Key result
Carvedilol administration for 30 days increased mean plasma atrial natriuretic peptide levels by 21.18% (from 37.60 to 45.83 pg/ml) in patients with moderate essential hypertension.
Why the study?
Does carvedilol increase atrial natriuretic peptide plasma levels in patients with moderate essential hypertension?
Does carvedilol increase atrial natriuretic peptide plasma levels in patients with moderate essential hypertension?
Absolute Event Rate: 45.83% vs 37.6%
Carvedilol increases plasma ANP levels in hypertensive patients, suggesting this is a primary effect of beta-blockade that contributes to its anti-hypertensive action.
May support ANP role in carvedilol effects; leaves open causality and clinical relevance in hypertension.
Twenty five patients with moderate essential hypertension were studied for 30 days in order to evaluate the medium term effects of carvedilol on atrial natriuretic peptide (ANP) levels. This drug blocks the β 1 and β 2 adrenenergic receptors as well as α 1 adrenergic receptors. In addition, it has strong antioxidative and antiproliferative properties. The drug was given orally at a dose of 12.5 mg b.i.d. Quantitative determination of human ANP was made by radioimmunoassay procedure (RIA). At the end of this clinical trial, mean plasma levels of ANP had risen during treatment by 21.18% (from 37.60 pg/ml to 45.83 pg/ml) while both systolic (SBP) and diastolic (DBP) blood pressure as well as diameters of the left cardiac cavities had decreased in a statistically significant way. The ratio ANP/SBP was also increased by 46.6% in a statistically significant way. These findings support the suggestion that the increase in plasma ANP following the administration of β-adrenergic blockers to hypertensive patients is a primary effect of beta blockade and not a mechanical one secondary to a negative inotropic action on the left ventricle and obviously contributes to the anti-hypertensive action.
No takes yet. Share an insight, caveat, or question.
Papadopoulos et al. (2007) studied Moderate essential hypertension (n=25). Carvedilol vs. Baseline (pre-treatment) was evaluated on Atrial natriuretic peptide (ANP) plasma levels. Carvedilol administration for 30 days increased mean plasma atrial natriuretic peptide levels by 21.18% (from 37.60 to 45.83 pg/ml) in patients with moderate essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: